212061-24-0

Basic information

• Product Name: Uridine, 5'-O-[(1,1-dimethylethyl)diphenylsilyl]-2'-O-(2-hydroxyethyl)-5-methyl-
• CAS NO: 212061-24-0
• Molecular Formula: C28H36N2O7Si
• Molecular Weight: 540.689
• Mol File: 212061-24-0.mol
• Article Data: 323

Chemical Properties

• CAS DataBase Reference: Uridine, 5'-O-[(1,1-dimethylethyl)diphenylsilyl]-2'-O-(2-hydroxyethyl)-5-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Uridine, 5'-O-[(1,1-dimethylethyl)diphenylsilyl]-2'-O-(2-hydroxyethyl)-5-methyl-(212061-24-0)
• EPA Substance Registry System: Uridine, 5'-O-[(1,1-dimethylethyl)diphenylsilyl]-2'-O-(2-hydroxyethyl)-5-methyl-(212061-24-0)

Safety Data

• Hazardous Substances Data: 212061-24-0(Hazardous Substances Data)

Upstream product

• 107-21-1 ethylene glycol 
• 171763-19-2 5'-O-tert-butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine 
• 853900-65-9 5'-O-tert-Butyldiphenylsilyl-O2-2'-anhydro-5-methyluridine 
• 134821-75-3 5′-O-tert-butyldiphenylsilyl-O²-2′-anhydro-5-methyluridine 
• 1463-10-1 5-Methyluridine 
• 26879-47-0 1-(β-L-ribofuranosyl)thymine 
• 244606-41-5 5'-O-tert-butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 22423-26-3 O-2,2'-cyclo-5-methyluridine 

Downstream Products

• 212061-25-1 5'-O-(tert-butyldiphenylsilyl)-2'-O-[2-[(2,3-dihydro-1,3-dioxo-1H-isoindol-2-yl)oxy]ethyl]-5-methyluridine 
• 317820-44-3 5'-O-(4,4'-dimethoxytrityl)-2'-O-[2-[(N,N-diethylamino)oxy]ethyl]-5-methyluridine 
• 212061-29-5 5'-O-(4,4'-dimethoxytrityl)-2'-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine 
• 317820-42-1 5'-O-(tert-butyldiphenylsilyl)-2'-O-[2-[(N,N-diethylamino)oxy]ethyl]-5-methyluridine 
• 317820-41-0 5'-O-tert-butyldiphenlsilyl-2'-O-[2-(acetaldoximinooxy)ethyl]-5-methyluridine 
• 400821-06-9 N⁴-benzoyl-3',5'-O-bis(tert-butyldiphenylsilyl)-2'-O-{2-[(N,N-dimethylamino)oxy]ethyl}-5-methylcytidine 
• 400821-05-8 3',5'-O-bis(tert-butyldiphenylsilyl)-2'-O-{2-[(N,N-dimethylamino)oxy]ethyl}-5-methylcytidine 
• 400821-04-7 3',5'-O-bis(tert-butyldiphenylsilyl)-2'-O-{2-[(N,N-dimethylamino)oxy]ethyl}-5-methyluridine 
• 315701-92-9 N⁴-benzoyl-2'-O-{2-[(N,N-dimethylamino)oxy]ethyl}-5-methylcytidine 
• 212061-26-2 2'-O-[(2-formadoxyiminooxy)ethyl]-5'-O-tert-butyldiphenylsilyl-5-methyluridine 
• 212061-27-3 5'-O-tert-butyldiphenylsilyl-2'-O-[N,N dimethylaminooxyethyl]-5-methyluridine 
• 258501-33-6 1-{5-(tert-butyl-diphenyl-silanyloxymethyl)-4-hydroxy-3-[2-(N-methyl-aminooxy)-ethoxy]-tetrahydro-furan-2-yl}-5-methyl-1H-pyrimidine-2,4-dione 

Relevant articles and documents

NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYERMASE

The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.

EFFECTS OF APOLIPOPROTEIN B INHIBITION ON GENE EXPRESSION PROFILES IN ANIMALS

Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided. Methods are provided for modulating the expression of genes involved in lipid metabolism, useful in the treatment of conditions associated with cardiovascular risk. Antisense oligonucleotides targeted to apolipoprotein B reduce the level of apolipoprotein B mRNA, lower serum cholesterol and shift liver gene expression profiles from those of an obese animal towards those of a lean animal. Further provided are methods for improving the cardiovascular risk of a subject through antisense inhibition of apolipoprotein B. Also provided are methods for employing antisense oligonucleotides targeted to apolipoprotein B to modulate a cellular pathway or metabolic process.

Antisense modulation of polo-like kinase expression

Antisense compounds, compositions and methods are provided for modulating the expression of polo-like kinase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding polo-like kinase. Methods of using these compounds for modulation of polo-like kinase expression and for treatment of diseases associated with expression of polo-like kinase are provided.